Prostate Cancer Features Archive

Prostate Cancer Diet and Dosage: How Much Could Patients Save?

Diet and Dosage: How Much Could Patients Save?

Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.

Prostate Cancer Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

Results from the Prostate Cancer Prevention Trial indicate that the reduced risk for prostate cancer among men assigned to finasteride continued throughout 16 years of follow-up.

General Oncology Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

General Oncology Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

Phase 1 trials should be considered therapeutic options for some patients.

Side Effect Management Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Prostate Cancer Confronting Racial Disparities in Prostate Cancer Survival Outcomes

Confronting Racial Disparities in Prostate Cancer Survival Outcomes

African Americans have a 60% higher incidence of prostate cancer and are about 2 times more likely to die from the disease.

General Oncology Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

General Oncology Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

General Oncology Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.

General Oncology Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Prostate Cancer Are Liquid Biopsies Trustworthy?

Are Liquid Biopsies Trustworthy?

A study could not determine whether one liquid biopsy panel is more accurate than another overall.

Side Effect Management Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

Prostate Cancer Emerging Therapies for Prostate Cancer

Emerging Therapies for Prostate Cancer

New diagnostic and therapeutic tools are in development to inform the management of advanced and metastatic disease.

General Oncology Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

General Oncology Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

Prostate Cancer Prostate Cancer: Hypofractionated Radiotherapy's Role in Post-operative Settings

Prostate Cancer: Hypofractionated Radiotherapy's Role in Post-operative Settings

Hypofractionated radiotherapy's role in postoperative settings remains unclear and awaits outcomes from ongoing studies.

General Oncology Does Immune Checkpoint Inhibition Have A Dark Side?

Does Immune Checkpoint Inhibition Have A Dark Side?

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

General Oncology Cannabis for Cancer: An Uncertain Future

Cannabis for Cancer: An Uncertain Future

While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.

General Oncology Can Understanding the Gut Microbiome Improve Clinical Oncology?

Can Understanding the Gut Microbiome Improve Clinical Oncology?

Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.

Prostate Cancer Prostate Cancer and Radiation Colitis

Prostate Cancer and Radiation Colitis

Up to 20% of patients with prostate cancer treated with radiation therapy — external or internal via brachytherapy — will develop radiation colitis.

Prostate Cancer The Potential of Radium-223 in Modern Prostate Cancer Treatment

The Potential of Radium-223 in Modern Prostate Cancer Treatment

More evidence may be needed to understand the safety and efficacy of radium-223 in combination with abiraterone or enzalutamide.

General Oncology Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.

General Oncology Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.

General Oncology The Warburg Effect: Can Cancer Be Starved of Sugar?

The Warburg Effect: Can Cancer Be Starved of Sugar?

A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.

Prostate Cancer Does Education Level Predict PSA Screening and Prostate Cancer Survival?

Does Education Level Predict PSA Screening and Prostate Cancer Survival?

Socioeconomic status, including education and income level, appears to be tied to prostate-specific antigen test results and prostate cancer treatment and survival, but the exact nature of these associations is not yet clear.

General Oncology Genetic Predisposition to Cancer: Where Are We Now?

Genetic Predisposition to Cancer: Where Are We Now?

In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.

General Oncology Mobile Apps: The Future of Cancer Care?

Mobile Apps: The Future of Cancer Care?

From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.

General Oncology Spontaneous Regression of Cancer: Explanations and Predictions

Spontaneous Regression of Cancer: Explanations and Predictions

Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.

Prostate Cancer Knowns and Unknowns in the Clinical Application of CTC Testing for Prostate Cancer

Knowns and Unknowns in the Clinical Application of CTC Testing for Prostate Cancer

Cancer Therapy Advisor asked Dr David Graham and Dr Alexander Kutikov about the state of the science of circulating tumor cell testing in prostate cancer, as well as this emerging field's potential clinical applications.

General Oncology Establishing Links Between Germline Mutations and Oncogenesis

Establishing Links Between Germline Mutations and Oncogenesis

In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.

General Oncology Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.

Prostate Cancer Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.

General Oncology Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

Prostate Cancer Racial Disparities in Prostate Cancer Outcomes: An Elusive Explanation

Racial Disparities in Prostate Cancer Outcomes: An Elusive Explanation

Increased insurance and clinical trial access, plus diversification of the medical workforce, may help to close treatment gaps.

General Oncology Malware in Medicine: Prevention Is Key to Protection

Malware in Medicine: Prevention Is Key to Protection

The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.

General Oncology Drug-herb and Drug-drug Interactions in Oncology

Drug-herb and Drug-drug Interactions in Oncology

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

Prostate Cancer Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.

General Oncology Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

Prostate Cancer Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

Circulating megakaryocytes are prognostic among patients with prostate cancer, bolstering evidence from breast cancer studies linking megakaryocytes to metastasis.

General Oncology Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?

Prostate Cancer Prostate Cancer Treatment: Abiraterone and Other Hormonal Therapies Being Studied

Prostate Cancer Treatment: Abiraterone and Other Hormonal Therapies Being Studied

More studies are needed to define the role of intratumoral androgen production and mCRPC resistance to hormonal therapies, and to determine if inhibitors of other steroidogenesis enzymes can be synergistic with abiraterone.

General Oncology Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.

Prostate Cancer Liquid Biopsy for Patients With Prostate Cancer May Determine Drug Treatment Response

Liquid Biopsy for Patients With Prostate Cancer May Determine Drug Treatment Response

A recent study suggests that a liquid biopsy may help oncologists to determine which patients with prostate cancer are likely to respond to enzalutamide or abiraterone.

General Oncology Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.

General Oncology Random Mutations May Be Leading Cause of Oncogenesis

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

Prostate Cancer Prostate Cancer: Treatment Choices and Patient-reported Outcomes

Prostate Cancer: Treatment Choices and Patient-reported Outcomes

Two recent studies provide men diagnosed with localized prostate cancer with important information about the adverse events of treatment choices.

General Oncology Proposed US Budget Cuts: Effects on Cancer Research

Proposed US Budget Cuts: Effects on Cancer Research

According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.

Prostate Cancer Non-invasive Biomarkers for Metastatic Prostate Cancer

Non-invasive Biomarkers for Metastatic Prostate Cancer

Can liquid biopsy and molecular imaging biomarkers help inform more precise management of patients with metastatic prostate cancer?

General Oncology Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history of immunotherapy.

General Oncology Incorporating Evolutionary Theory Into Oncology

Incorporating Evolutionary Theory Into Oncology

Oncologists, drug developers, and evolutionary theorists could collaborate to design treatments and treatment combinations that are more likely to succeed given the laws of natural selection.

General Oncology Treeomics: A Mathematical Tool for Predicting Metastases

Treeomics: A Mathematical Tool for Predicting Metastases

Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.

Genitourinary Cancers Symposium 2017 Explaining Androgen Receptor-indifferent Prostate Cancer

Explaining Androgen Receptor-indifferent Prostate Cancer

Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.

Prostate Cancer Prostate Cancer: In Search of Predictive Biomarkers for Immunotherapy

Prostate Cancer: In Search of Predictive Biomarkers for Immunotherapy

Scientists are testing immune checkpoint proteins, CD8 T cell clonal expansion, mutational load, and PSA levels as predictive biomarkers for prostate cancer immunotherapy outcomes.

Prostate Cancer PSA Nadir Identifies High-risk Cases of Localized Prostate Cancer

PSA Nadir Identifies High-risk Cases of Localized Prostate Cancer

PSA nadir greater than 0.5 ng/mL may serve as a surrogate marker to identify men with localized prostate cancer at high risk of mortality.

Prostate Cancer Prostate Cancer: Future of Research and Treatment

Prostate Cancer: Future of Research and Treatment

Recent discoveries of germline mutations are driving research in novel treatments, including immunotherapies, for prostate cancer.

Prostate Cancer Radiogenomics: Biomarkers for Prostate Cancer Radiotherapy Outcomes

Radiogenomics: Biomarkers for Prostate Cancer Radiotherapy Outcomes

Researchers are making progress in the search for biomarkers that can help identify which patients are most likely to benefit from radiotherapy.

Prostate Cancer Metastatic Prostate Cancer to the Gastrointestinal Tract

Metastatic Prostate Cancer to the Gastrointestinal Tract

Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which limit treatment options.

General Oncology Vitamin D and Cancer: An Unclear Relationship

Vitamin D and Cancer: An Unclear Relationship

According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.

Prostate Cancer GATA2 in Prostate Cancer: A Promising Biomarker

GATA2 in Prostate Cancer: A Promising Biomarker

The pioneer transcription factor GATA2 has been implicated in prostate tumorigenesis, tumor aggressiveness, treatment resistance, and metastasis, making it a promising biomarker.

General Oncology The Dashboard of Happiness

The Dashboard of Happiness

Dr Barbara Burtness of Yale University's School of Medicine discusses the relationship between happiness and clinical practice in oncology.

General Oncology Survival After Pediatric Cancer: Reducing the Lifetime Burden

Survival After Pediatric Cancer: Reducing the Lifetime Burden

A study of self-reported health status shows the need for physicians to consider the overall well-being of pediatric cancer survivors, for life.

General Oncology Determining the Role of Gender in Oncology Trial and Treatment Outcomes

Determining the Role of Gender in Oncology Trial and Treatment Outcomes

Differences between the sexes are known in a variety of cancers, but the reasons remain unclear.

Supportive Care Seven States Approve Some Form of Marijuana Initiative

Seven States Approve Some Form of Marijuana Initiative

CTA spoke with Judith A. Paice, PhD, RN, to better understand how clinicians are reacting to these legalizations and how she responds to patients asking about cannabis use.

General Oncology Watson: A Glorified Search Engine?

Watson: A Glorified Search Engine?

Watson, hoped to be a major source for clinicians, is limited by an inability to interpret clinical trials.

General Oncology Is Drugmaker Funding for Patient Groups a Hidden Culprit in Rising Drug Prices?

Is Drugmaker Funding for Patient Groups a Hidden Culprit in Rising Drug Prices?

Drugmaker funding for patient advocacy groups might be an important but neglected factor in rising drug prices.

Prostate Cancer Developing microRNA Biomarkers for Prostate Cancer

Developing microRNA Biomarkers for Prostate Cancer

Short, noncoding regulatory stretches of RNA known as microRNA hold promise as prostate cancer biomarkers.

Prostate Cancer Looking to the Genome for Prostate Cancer Biomarkers

Looking to the Genome for Prostate Cancer Biomarkers

Researchers are trying to develop prostate cancer biomarkers that can predict treatment effects, to spare patients toxicities associated with unhelpful regimens.

General Oncology Clinical Trial Reporting in the United States: Limitations of Strained Resources

Clinical Trial Reporting in the United States: Limitations of Strained Resources

Guidelines and technology are changing, but as the number of clinical trials increases, ensuring that trials are reported will be an increasingly difficult task.

General Oncology Darwinian Oncology Comes of Age: Evolutionary Biologists Offer Competing Theories of Cancer

Darwinian Oncology Comes of Age: Evolutionary Biologists Offer Competing Theories of Cancer

Proponents of competing evolutionary theories seek to explain—and combat—oncogenesis.

General Oncology Financial Hardship Common Among Cancer Survivors and Warrants Patient-Provider Discussion

Financial Hardship Common Among Cancer Survivors and Warrants Patient-Provider Discussion

Financial hardship is common among cancer survivors in the US, and can be a psychologically and economically debilitating burden.

Side Effect Management New Online Tool May Reduce Cancer Survivors' Cognitive Impairment From Chemotherapy

New Online Tool May Reduce Cancer Survivors' Cognitive Impairment From Chemotherapy

This inexpensive, web-based treatment may help patients overcome cognitive issues from chemotherapy.

General Oncology Education Is Paramount for Cancer Prevention

Education Is Paramount for Cancer Prevention

Educating the public about risk factors and prevention strategies remains a major challenge to cancer prevention.

General Oncology Genomic Information and the Future of Health Care

Genomic Information and the Future of Health Care

Embracing all the myriad variations of the human genome should, in theory, lead to rewards that all can share.

General Oncology The Role of Microbes in Oncogenesis and the Treatment of Cancer

The Role of Microbes in Oncogenesis and the Treatment of Cancer

Researchers are identifying new roles for infectious and commensal microbes in facilitating and inhibiting carcinogenesis.

Prostate Cancer Despite USPSTF Recommendation, PSA Screening Sticking Around

Despite USPSTF Recommendation, PSA Screening Sticking Around

Prostate-specific antigen screening is not meaningfully less frequent than before guidelines were issued against use of the test.

General Oncology Is Indication-specific Pricing for Cancer Drugs on the Horizon?

Is Indication-specific Pricing for Cancer Drugs on the Horizon?

At War on Cancer, numerous figures in cancer care discussed innovations to reduce the costs associated with drugs.

Prostate Cancer Immunotherapies' Disappointing Track Record for Prostate Cancer

Immunotherapies' Disappointing Track Record for Prostate Cancer

After a litany of failures for immunotherapies against prostate cancer, calls are mounting for approaches that combine these agents with other treatments.

Prostate Cancer Metastasis More Than Doubles With Monitoring Instead of Treatment for Localized Prostate Cancer

Metastasis More Than Doubles With Monitoring Instead of Treatment for Localized Prostate Cancer

Contrary to some news headlines, monitoring prostate cancer has different survival implications than treatment after 10 years.

Prostate Cancer Q&A With Samanta Kumar Pal, MD: Prostate Cancer Androgen Deprivation and "Drug Holidays"

Q&A With Samanta Kumar Pal, MD: Prostate Cancer Androgen Deprivation and "Drug Holidays"

In this Q&A, CTA asked Dr Pal about the ongoing controversy, evidence base, and pivotal studies of intermittent versus continuous androgen deprivation therapy for prostate cancer.

General Oncology 2016 Concordia Summit: The Future of Immunotherapy

2016 Concordia Summit: The Future of Immunotherapy

Speakers at the 2016 Concordia Summit's panel, "Precision Medicine in Cancer Research," discussed the importance and future of immunotherapy for cancer treatment.

General Oncology Q&A With Dana Carroll, PhD, Highlights CRISPR's Growing Role in Genome Editing

Q&A With Dana Carroll, PhD, Highlights CRISPR's Growing Role in Genome Editing

In this question-and-answer session, CTA asked Dr Carroll about CRISPR-Cas9, the state of the science of genome editing, and its implications for oncology.

General Oncology The Evolutionary Implications of CRISPR-Cas9 for Clinical Oncology

The Evolutionary Implications of CRISPR-Cas9 for Clinical Oncology

CRISPR is receiving attention as a gene-editing tool that may help us treat cancer, but evolutionary theory suggests a much more complex reality.

General Oncology Enforcing Reproducibility Improves the Accuracy of Scientific Predictions

Enforcing Reproducibility Improves the Accuracy of Scientific Predictions

Overselling scientific data contributes to misunderstanding, failure, and disappointment in real-world settings.

General Oncology Poor Sleep Quality Associated With Symptom Burden Among Phase 1 Trial Participants

Poor Sleep Quality Associated With Symptom Burden Among Phase 1 Trial Participants

Patients who slept poorly exhibited greater symptom burden and overall mood disturbance.

General Oncology PAP Series: Patient Assistance Programs "Culprits" of Rising Drug Prices

PAP Series: Patient Assistance Programs "Culprits" of Rising Drug Prices

The federal government is investigating some drugmakers' relationships with the charities that run assistance programs.

Prostate Cancer Should We Abandon PSA Testing Or Make it More Targeted?

Should We Abandon PSA Testing Or Make it More Targeted?

Widespread contamination of the Prostate, Lung, Colorectal, and Ovary (PLCO) Cancer Screening Trial has reignited the debate around prostate-specific antigen testing.

Side Effect Management Patient Preferences: More Complex Than Maximizing Survival Time

Patient Preferences: More Complex Than Maximizing Survival Time

Quantifications of quality of life or patient-reported outcomes will offer more information for treatment-planning discussions.

Prostate Cancer Robotic Surgery for Prostate Cancer May Not Improve Quality of Life

Robotic Surgery for Prostate Cancer May Not Improve Quality of Life

Sexual function scores do not appear to differ between the 2 groups at 6 weeks or 12 weeks post-surgery, and no significant differences were found for bowel quality of life or pathological outcomes.

General Oncology Evolutionary Logic May Aid the Development of Cancer Therapies

Evolutionary Logic May Aid the Development of Cancer Therapies

Humans can tolerate tumors in large or paired organs more easily than in small, critical organs, and the larger organs may therefore have evolved fewer mechanisms to defend against cancerous cells.

Prostate Cancer Q&A With Emmanuel Antonarakis, MD: AR-V7 "Liquid Biopsy" Can Avoid Unneeded Treatment, Curb Health Care Costs

Q&A With Emmanuel Antonarakis, MD: AR-V7 "Liquid Biopsy" Can Avoid Unneeded Treatment, Curb Health Care Costs

AR-V7 has been implicated in metastatic prostate tumor resistance to the androgen-receptor signaling (ARS) blockers abiraterone and enzalutamide.

General Oncology The Future of the Biomedical Research Workforce in the United States

The Future of the Biomedical Research Workforce in the United States

As our aging workforce expands, a decreasing number of young investigators are applying for National Institute of Health (NIH) R01-equivalent grants.

Prostate Cancer Era of Precision Oncology for Prostate Cancer 'Is Upon Us'

Era of Precision Oncology for Prostate Cancer 'Is Upon Us'

New biomarkers might revolutionize prostate cancer treatment, according to an educational presentation at the 2016 ASCO Annual Meeting in Chicago.

Prostate Cancer Presence of P. acnes In Prostate Tissue Associated With Prostate Cancer

Presence of P. acnes In Prostate Tissue Associated With Prostate Cancer

Men with P. acnes found in their prostate tissue biopsy are more than 4 times as likely to develop prostate cancer as others.

General Oncology Novel Toxicity Examinations for Patients Treated With Targeted Therapies

Novel Toxicity Examinations for Patients Treated With Targeted Therapies

Instead of analyzing adverse events (AEs) in the traditional fashion, we ought to consider alternatives in this new era of personalized medicine.

Prostate Cancer New Method Helps Identify Neighborhood Factors Associated With Aggressive Prostate Cancer

New Method Helps Identify Neighborhood Factors Associated With Aggressive Prostate Cancer

Using a new methodology called a "neighborhood-wide association study," researchers have identified 17 variables, out of more than 14,600, that were significantly associated with prostate cancer aggressiveness.

General Oncology Senescent Effects on Cancer Cells Are Context-dependent

Senescent Effects on Cancer Cells Are Context-dependent

The senescence-associated secretory phenotype can promote tumorigenesis under certain conditions, and may offer a target for senolytic therapy.

General Oncology ASCO Issues Policy Statement on Curbing Abuse of Opioids

ASCO Issues Policy Statement on Curbing Abuse of Opioids

ASCO states that it supports Congress, the Obama Administration, and multiple federal agencies in their efforts to prevent and respond to prescription drug abuse.

Prostate Cancer Preventing Overtreatment of Prostate Cancer: New Model Identifies Ideal Patients for Active Surveillance

Preventing Overtreatment of Prostate Cancer: New Model Identifies Ideal Patients for Active Surveillance

A new care model for patients with low-risk prostate cancer may help prevent disease overtreatment.

General Oncology Liquid Biopsy to Detect BRAFV600 Mutations in Advanced Cancers Shows Promise

Liquid Biopsy to Detect BRAFV600 Mutations in Advanced Cancers Shows Promise

Investigators found that cell-free DNA is released into circulation by cancer cells undergoing apoptosis or necroptosis in the primary or metastatic cancer lesions.

General Oncology Immunotherapy Q&A Session With Aude G. Chapuis, MD

Immunotherapy Q&A Session With Aude G. Chapuis, MD

How will breakthroughs in vaccine-based immunotherapies and the National Cancer Moonshot Initiative impact clinical practice?

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs